
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health is well-positioned in the growing market for value-based care and population health management, as evidenced by its partnership with UPMC Health Plan and The Advisory Board Company, and its expanding suite of solutions in areas such as oncology, cardiology, and musculoskeletal care. With strong financials and a growing demand for its services, EVH has an estimated 25% revenue growth for 2027 and a de-risked adjusted EBITDA of $150 million. Despite potential risks such as utilization and new contract wins, we maintain a Buy rating on EVH due to its improved visibility and attractive valuations.
Bears say
Evolent Health is facing headwinds, with a recent $90 million increase in commercial revenue appearing unimpressive compared to their $60 million increase in Medicare. Additionally, the company is seeing decline in Medicaid and HIX business, and uncertainties surrounding Medicaid work requirements pose a significant threat. These factors, along with the company's declining margins and slow margin maturation, lead to a negative outlook for Evolent Health's stock.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares